Page 2 - Metastasis Program News Today

The increased viscosity, or resistance to movement, of the extracellular fluid that surrounds cells allows cancer cells to migrate more quickly from a primary tumour to other areas in the body, according to new research findings.

Scientists have discovered how cancer cells exposed to high viscosity environments change their movements to improve their invasiveness and favor metastases.

New research findings show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.

Studying a deadly type of breast cancer called triple negative, Johns Hopkins Medicine scientists say they have identified key molecular differences between cancer cells that cling to an initial tumor and those that venture off to form distant tumors.

New findings clarify why triple negative breast cancer is so resistant to treatment.

Aging and age-related disorders pose a complex challenge to the biomedical research community. To better understand how senescence is regulated is of high significance to promote healthy aging and treat age-associated disorders.

Due to the development of resistance to chemotherapy and recurring tumors, patients with ovarian cancer often have low survival rates.

Immunotherapies have shown striking clinical benefit in the treatment of many cancers, especially when used in combination with chemotherapy.

Genomic Test Helps Guide Precision Medicine to Estimate Risk of Prostate Cancer Metastasis, Death February 11, 2021 San Francisco, CA (UroToday.com) -- A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers. Researchers studied prostate cancer samples from 352 participants in the NRG/RTOG 9601 ...

(1) BEDMINSTER, N.J., Jan. 15, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with The Wistar Institute, an international leader in biomedical research, to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context ...